Sign In

Use the Qualified Clinical Data Registry (QCDR) to complete Merit-Based Incentive Payment System reporting.

Report on evidence-based quality measures and receive performance scores via the Quality Oncology Practice Initiative (QOPI®).

Oncology Practice Insider

ASCO’s Oncology Practice Insider provides the latest news, information, and educational tools to assist with the successful management of oncology practice and the delivery of high quality patient care. OPI offers updates on ASCO programs, services, and cancer-related health policy, Medicare news, and billing and coding best practices. To sign up for the biweekly Oncology Practice Insider newsletter, please complete this form.

On July 3, 2019, the Food and Drug Administration granted accelerated approval to selinexor (XPOVIO, Karyopharm Therapeutics) in combination with dexamethasone for adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody. Read more.
Open Payments data reported in 2018 is now publicly available on CMS’ website. While the pre-publication review and dispute period has passed, U.S. physicians have until December 31, 2019 to review and dispute 2018 data reported in their name. As a reminder, data can only be disputed in the year it is made public. ASCO’s disclosure database now allows you to include a link to your Open Payments page.
On June 17, ASCO posted the Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision-Making for Early-Stage, Operable Breast Cancer Guideline Update. A podcast interview with ASCO’s Guideline Co-Chair explains the content of the update.
Exciting plans for this year’s Research Community Forum (RCF) Annual Meeting are highlighted in a new ASCO Connection blog post by RCF Steering Group Chair David Waterhouse, MD​, including presentations,  collaborative sessions, and a Keynote Address delivered by FDA Oncology Center of Excellence Director, Richard Pazdur, MD. Read the blog. 
On June 27, 2019, the Food and Drug Administration approved daratumumab (DARZALEX®, Janssen Biotech, Inc.) in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant. Read more. 
The Director of FDA’s Oncology Center of Excellence, Dr. Richard Pazdur, joins ASCO CEO Dr. Clifford A. Hudis in the latest ASCO in Action Podcast to discuss FDA’s new program to make it easier for physicians to navigate the complicated expanded access process.
CMS is hosting two upcoming webinars that will provide engaging and informative overviews about quality measures, with an emphasis on how these measures are impacting health care and how the public can get involved in the development of quality measures. Both webinars will be offered twice this summer. Be sure to register in advance as space is limited. Measuring Quality to Improve Quality: Strengths and Challenges of Clinical Quality Measurement
On May 17, 2019, the Centers for Medicare and Medicaid Services announced they will be delaying the publication of final National Coverage Determination (NCD) in regards to CAR-T therapy. The proposed decision and stakeholder comments have been posted online.